Suppositories: The Incomplete Story - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Suppositories: The Incomplete Story
A reference book omits important information and ignores advanced testing procedures.


Pharmaceutical Technology


Suppositories, Loyd V. Allen, Jr., Ed., Pharmaceutical Press, London, 2008, 245 pp., ISBN 978 0 85369 646 9.
Loyd V. Allen Jr., a well-known compounding expert, has edited a book titled Suppositories for professional compounding centers, hospital pharmacies, and compounding pharmacists in retail pharmacies. Although the book provides useful information, its omissions and idiosyncracies prevent it from being "an essential resource for all those involved in the formulation, development, manufacture, and testing of suppositories," as Allen describes the book.

The preface reveals one of the book's shortcomings when it explains that the literature review is limited to the last 25 years. The limitation is apparent in an early chapter that gives a detailed introduction to modern suppository bases. The chapter includes long tables of marketed products and their specifications, but offers no reasons for the huge variety of marketed bases. This may be a consequence of ignoring the patent literature published between 1950 and 1970.

Nor does the chapter explain which are the most important bases and what their special advantages are in different formulations. The European Pharmacopoeia topic of hard fat, as a collective name for semisynthetic triglycerides, is also not mentioned, which is surprising because the book's publisher is British.

A later chapter offers a detailed primer about compounding suppositories. It includes much practical advice for daily work such as the preparation of the active ingredient Peru Balsam.

On the other hand, the book does not propose that compounders use distinct bases for different tasks. For example, the book does not explain the importance of bases' different melting points or hydroxyl values. Also, the section titled "Preparation by Hand Rolling and Shaping" seems unusual in a book published in 2008.

A chapter called "Special Types of Suppositories" gives an overview of vaginal suppositories and tablets and urethral suppositories. The chapter discusses controlled-release, prolonged-release, and sustained-release suppositories without drawing clear distinctions between them.

The book cites many Japanese publications about hollow suppositories that incorporate a shaft filled with a second, mostly oleaginous, phase. These citations are remarkable because this technique allows the production of suppositories with incompatible ingredients.

Numerous techniques for examining and testing suppositories, as well as simulation of their in vivo melting behavior and drug release, are described in a section about quality control. The section sketches out a simplified test procedure for compounded suppositories. A problem of this chapter is that the author proposes no distinct testing procedure for branded products beyond that described in the US Pharmacopeia. The reader should know about the European Pharmacopoeia's modern specifications, but they are not mentioned.

Advice for patients and consumers is the focus of the "Clinical Considerations" chapter. The largest part of the chapter describes contemporary clinical-effectiveness studies of suppositories containing active ingredients from acetaminophen to verapamil.

Suppositories provides a detailed primer for compounding pharmacists in the US. The literature review about biopharmaceutics and pharmacokinetics may be of interest to pharmaceutical technologists in industry or at universities. Aside from that feature, the book offers little help for the pharmaceutical professional who researches, develops, or produces dosage forms, contrary to the author's intention.

Heinz Sucker is professor emeritus at the University of Bern, Bernerring 70 CH-4054 Basel, Switzerland, tel. 141 61 281 0084,
He also is a member of Pharmaceutical Technology's editorial advisory board.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here